In short
Jennifer Bittinger, President of Narrativa, argues that AI can dramatically shorten the clinical trial process by automating the regulatory documentation that slows drugs on their way to market. Drawing on her company's work turning trial data into patient narratives, she frames the opportunity around three principles for disruptors: don't fear disrupting the process, run toward the crisis, and let your competitors sharpen you.
Key takeaways
- The decade of artificial intelligence: don't be afraid to disrupt the process.
- Crisis also means opportunity: run toward the problem and provide the solution.
- Love your neighbor: embrace your competitors and let them sharpen you to greatness.
AI is older than the headlines suggest
Bittinger opens by correcting a common assumption. Watching the news, many people believe AI appeared in the last year or two. "Actually, it's been around for almost close to a century." (0:44)
She traces the story from the first AI program, developed in 1951 by Christopher Strachey, who later led a programming research group at the University of Oxford, through the supercomputer age of the 1960s to 1980s, when entire rooms held a single machine and deep learning techniques emerged. The processing chips of the 1990s then gave that hardware the speed to handle large amounts of data, increasing data volume, advancing algorithms and improving computing power and storage.
That history leads to Narrativa, founded in 2015 on the idea of using natural language generation and natural language processing to turn data into text and back again. Its work ranges from stock market articles for The Wall Street Journal to summaries of thousands of white papers and, most importantly for this talk, regulatory documentation for clinical trials. Bittinger describes the company's founding premise as using technology for good, and suggests that women in technology, as disruptors in their industries, should share that mission.
The problems COVID-19 exposed
Bittinger calls COVID-19 one of the worst events her generation had seen, but says it forced the life sciences industry to see that the long, laborious process of getting drugs and vaccines to market had to change. She names three problems in clinical trial regulatory documentation.
First, the timeline: as she cited, getting one drug from the start of research to regulatory approval takes 12 to 15 years on average. Second, budgets: she puts the cost of one drug at $1 billion to $1.5 billion. "The reason this is ridiculous is because it hits your pocketbook and my pocketbook when it comes to pharmaceuticals." (5:50)
Third, error and risk. As the speaker cited, on average 40 to 50% of clinical trial data and documentation contains errors, largely because organizations run so many trials at once. She shows how hard it is for a biostatistician, statistical analyst or programmer to work through mountains of data sets and produce a patient narrative by hand.
Crisis meets opportunity
Here Bittinger applies her second principle. "So we said okay crisis meets opportunity run towards the problem in the Chinese language I love that the symbol for crisis is the same symbol for opportunity." (6:42)
Narrativa's answer was to automate clinical trial documentation. She reports that the company has been seeing at least a 65% reduction in time when that documentation is automated, along with lower budgets and less human error and risk. The work runs through a no-code SaaS platform that medical writers, biostatisticians, statistical analysts and programmers can all use to generate clinical trial reports, as well as articles, white papers and marketing materials for sales teams. She describes it as being like a personal marketplace.
Love your neighbor, especially your competitors
The third principle is the least expected. Bittinger admits it sounds like a kindergarten lesson, but argues that the people who help a company grow most are its competitors. As one of the first AI companies in its market, Narrativa had the hard job of educating customers about AI on its own. "So we needed competitors to help educate the market about AI." (8:20)
Competitors also helped with pricing. "So know what your competitors are pricing." (8:40) And over the long run, she says, competition drives innovation for an entire industry, beyond any one person's lifetime.
A first for AI-generated regulatory documentation
Bittinger closes with a use case. Narrativa had just finished a drug trial for The Leukemia & Lymphoma Society in which it automated all of the patient narratives. She explains that it was set to be the society's first clinical trial to go to the FDA with fully AI-generated regulatory documentation, which she describes as a milestone not only for the two organizations but for the wider world.
Her final message moves beyond efficiency. She encourages the audience to accelerate the potential of AI not only to shorten timelines and reduce budgets, but ultimately to save lives. "I encourage you to do everything you can, not just to make a difference in your own wallet or in your budget, but make a difference in the lives of people around you." (9:30)
Watch the talk
Supercharging the Clinical Trial Process Through the Power of AI, Jennifer Bittinger, 10 minutes: https://www.womentech.net/video/supercharging-clinical-trial-process-through-power-ai
About the speaker
Jennifer Bittinger is President of Narrativa, an international AI technology company bringing artificial intelligence automation to industries including Life Sciences, Finance, MarTech, Gaming and AEC. She brings 20 years of experience in media, tech, marketing and public relations, including work as a VP of Marketing and branded content specialist for clients such as ExxonMobil, Hulu, OWN and the San Francisco Giants.
Questions this talk answers
- Why does bringing a drug to market take so long and cost so much?
- How can AI help speed up clinical trials?
- Is artificial intelligence a new technology?
- Why should a company embrace its competitors?
- What milestone has AI-generated regulatory documentation reached?
Drafted with AI from the talk transcript. Editor review pending.